ICICI Direct expects revenue CAGR of 35.6% over FY22-FY24E mainly due to the consolidation of Viatris business and they expect EBITDA margin expansion of 230bps and earnings CAGR of 64.8% over FY22-FY24E
Aflibercept is the second biosimilar product that has entered the clinical trial phase after biosimilar Adalimumab
Marks the second of three biosimilars Amneal expects to receive U.S. approval for in 2022
Intas has developed a biosimilar of Lucentis, which is currently under Phase III global trial for submission in major countries including EMA & the US
Celerity Pharmaceuticals uses Biocon Biologics’ insulin drug substance to develop the product
The study met its primary endpoint and showed equivalent efficacy and a comparable safety profile
Alvotech expects AVT02 (adalimumab) will be marketed in the U.S., subject to regulatory approval, on July 1, 2023
First of three Amneal biosimilars expected for U.S. approval and launch in 2022
BBL will gain Viatris’ global biosimilars business whose revenues are estimated to be USD 1 billion next year, along with its portfolio of in-licensed biosimilar assets
Under the terms of the agreement, Biogen will make an upfront payment of US $ 8 million to Xbrane
Subscribe To Our Newsletter & Stay Updated
